AusBiotech maintains pressure on regulatory reforms

Australian trade group AusBiotech has waited a decade for regulatory reforms to reduce costs and administrative burden for the industry, but it is not giving up the push to see them implemented as quickly as possible.

The group has made a submission to Australia’s Senate Inquiry on the Therapeutic Goods Amendment (2016 Measures No 1) Bill 2016, urging that the bill be supported to enable regulatory reform measures stemming from the review of Medicines and Medical Devices Regulation (MMDR).

AusBiotech is supportive of the MMDR’s regulatory reforms and efforts to make the assessment process shorter and simpler, while maintaining the safety and quality of medicines and medical devices.